(Reuters) – The U.S. Food and Drug Administration on Thursday warned consumers not to use counterfeit versions of Novo Nordisk’s diabetes drug Ozempic that have been found in the country’s drug supply chain.
The health regulator said it continues to investigate counterfeit injections and has seized thousands of units of the product.
Novo Nordisk and the FDA are testing the seized products and do not yet have information about the drugs’ identity, quality or safety, the agency said.
(Reporting by Sriparna Roy and Bhanvi Satija in Bengaluru; Editing by Shounak Dasgupta and Krishna Chandra Eluri)
